Christopher Simon, - Insider Trading Tracker

Introduction

This page provides a comprehensive analysis of the known insider trading history of Christopher Simon,. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

Companies with Reported Insider Positions

The SEC filings indicate Christopher Simon, has reported holdings or trades in the following companies:

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Christopher Simon,. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases HAE / Haemonetics Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in HAE / Haemonetics Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2016-08-04	HAE	Simon, Christopher	60,000	34.9959	60,000	34.9959	2,099,754	274	43.2000	492,246	23.44

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales HAE / Haemonetics Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in HAE / Haemonetics Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2022-06-13	HAE	Simon, Christopher	1,148	62.6000	1,148	62.6000	71,865	3	59.2800	-3,811	-5.30
2022-05-19	HAE	Simon, Christopher	2,496	59.1000	2,496	59.1000	147,514
2022-05-16	HAE	Simon, Christopher	832	56.1000	832	56.1000	46,675
2021-06-14	HAE	Simon, Christopher	1,200	59.8700	1,200	59.8700	71,844
2021-06-07	HAE	Simon, Christopher	2,715	55.0900	2,715	55.0900	149,569
2021-05-19	HAE	Simon, Christopher	1,024	55.1900	1,024	55.1900	56,515
2021-05-17	HAE	Simon, Christopher	956	55.9700	956	55.9700	53,507
2020-06-30	HAE	Simon, Christopher	5,084	87.7900	5,084	87.7900	446,324
2020-06-15	HAE	Simon, Christopher	45,723	87.7100	45,723	87.7100	4,010,364
2020-06-12	HAE	Simon, Christopher	1,294	89.2900	1,294	89.2900	115,541
2020-06-08	HAE	Simon, Christopher	2,920	97.0300	2,920	97.0300	283,328
2020-05-15	HAE	Simon, Christopher	1,008	100.4400	1,008	100.4400	101,244
2019-08-19	HAE	Simon, Christopher	50,869	137.4300	50,869	137.4300	6,990,927
2019-07-01	HAE	Simon, Christopher	5,008	121.7900	5,008	121.7900	609,924
2019-06-12	HAE	Simon, Christopher	1,248	109.3700	1,248	109.3700	136,494
2019-06-07	HAE	Simon, Christopher	2,834	103.3800	2,834	103.3800	292,979
2019-05-23	HAE	Simon, Christopher	24,412	99.3900	24,412	99.3900	2,426,309
2019-05-13	HAE	Simon, Christopher	57,587	94.5100	57,587	94.5100	5,442,547
2018-07-02	HAE	Simon, Christopher	5,139	89.3100	5,139	89.3100	458,964
2018-06-07	HAE	Simon, Christopher	1,941	92.7300	1,941	92.7300	179,989
2017-06-29	HAE	Simon, Christopher	3,595	40.3900	3,595	40.3900	145,202

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Purchases SHC / Sotera Health Company - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in HAE / Haemonetics Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales SHC / Sotera Health Company - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in HAE / Haemonetics Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Christopher Simon, as disclosed to the Securities Exchange Commission (SEC).